17DD yellow fever vaccine: A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 879-888

  Martins, Reinaldo M ^a   Maia, Maria De Lourdes S ^a   Farias, Roberto Henrique G ^a   Camacho, Luiz Antonio B ^b   Freire, Marcos S ^a   Galler, Ricardo ^a   Yamamura, Anna Maya Yoshida ^a   Almeida, Luiz Fernando C ^a   Lima, Sheila Maria B ^a   Nogueira, Rita Maria R ^b   Sá, Gloria Regina S ^a   Hokama, Darcy A ^a   De Carvalho, Ricardo ^a   Freire, Ricardo Aguiar V ^c   Filho, Edson Pereira ^c   Da Luz Fernandes Leal, Maria ^a   Homma, Akira ^a  

^a Instituto de Technologia em Imunobiologicos   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Instituto de Biologia do Exercito   (Brazil)

Author keywords

Bio Manguinhos Fiocruz; Dengue interactions; Dose response study; Immunogenicity; Reactogenicity; Safety; Viremia; Yellow fever vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; FATIGUE; HUMAN; HYPEREMIA; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PAIN; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; YELLOW FEVER;

BIO-MANGUINHOS/FIOCRUZ; DENGUE INTERACTIONS; DOSE-RESPONSE STUDY; IMMUNOGENICITY; REACTOGENICITY; SAFETY; VIREMIA; YELLOW FEVER VACCINE;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTHY VOLUNTEERS; HUMANS; MALE; TIME FACTORS; VACCINATION; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 84877131919     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22982     Document Type: Article

References (38)

1. Marchevsky RS, da Luz Leal M, Homma A, Coutinho ESF, Camacho LAB, Jabor AV, et al. Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos. Biologicals 2006; 34:191-7; PMID:16326110; http://dx.doi.org/10.1016/j.biologi-cals.2005.09.005.
2. Stock NK, Boschetti N, Herzog C, Appelhans MS, Niedrig M. The phylogeny of yellow fever virus 17D vaccines. Vaccine 2012; 30:989-94; PMID:22197965; http://dx.doi.org/10.1016/j.vaccine.2011.12.057.
3. World Health Organization. Who Technical Report Series 872, Annex 2, Requirements for yellow fever vaccine, 1998.
4. World Health Organization. Expert Committee on Biological Standardization. Requirements for yellow fever vaccine (Requirements for Biological Substances n° 3). WHO, 2008.
5. Fox J P, Kossobudzki SL, Cunha J F. Field studies of the immune response to 17D yellow fever virus. Am J Hyg 1943; 38:113-38.
6. Smith CE, Turner LH, Armitage P. Yellow fever vaccination in Malaya by subcutaneous injection and multiple puncture. Neutralizing antibody responses in persons with and without pre-existing antibody to related viruses. Bull World Health Organ 1962; 27:717-27; PMID:13993152.
7. Lopes O de S, Guimarães SSDA, de Carvalho R. Studies on yellow fever vaccine. III-Dose response in volunteers. J Biol Stand 1988; 16:77-82; PMID:3372545; http://dx.doi.org/10.1016/0092-1157(88)90034-0.
8. Freestone DS, Ferris RD, Weinberg AL, Kelly A. Stabilized 17D strain yellow fever vaccine: dose response studies, clinical reactions and effects on hepatic function. J Biol Stand 1977; 5:181-6; PMID:893464; http://dx.doi.org/10. 1016/S0092-1157(77)80003-6.
9. Monath T P, Cetron MS, Teuwen DE. Yellow fever vaccines. In: Plotkin S, Orenstein W, Offit P. Vaccines, 5th ed, Saunders Elsevier, China, 2008, p. 959-1055.
10. Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 1999; 4:867-71; PMID:10632996; http://dx.doi.org/10.1046/j.1365-3156.1999.00496.x.
11. Poland JD, Calisher CH, Monath T P, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981; 59:895-900; PMID:6978196.
12. Groot H, Ribeiro RB. Neutralizing and haemaggluti-nation-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ 1962; 27:699-707; PMID:13950710.
13. de Melo AB, da Silva M da P, Magalhães MCF, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, et al. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 2011; 85:739-47; PMID:21976581; http://dx.doi.org/10.4269/ajtmh.2011.10-0496.
14. Camacho LAB, Freire M da S, Leal M da L, Aguiar SG, Nascimento J P, Iguchi T, et al.; Collaborative Group for the Study of Yellow Fever Vaccines. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004; 38:671-8; PMID:15499438; http://dx.doi.org/10. 1590/S0034-89102004000500009.
15. Santos A P, Bertho AL, Dias DC, Santos JR, Marcovistz R. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus. Mem Inst Oswaldo Cruz 2005; 100:331-7; PMID:16113878; http://dx.doi.org/10.1590/ S0074-02762005000300021.
16. Smith HH, Penna HA, Paoliello A. Yellow fever vaccination with cultured virus (17D) without immune serum. Am J Trop Med 1938; 18:437-68.
17. Sweet BH, Wisseman CL Jr., Kitaoka M, Tamiya T. Immunological Studies with group B arthropod-borne viruses. II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subjects following administration of 17D yellow fever vaccine. Am J Trop Med Hyg 1962; 11:562-9.
18. Wheelock E F, Sibley WA. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. N Engl J Med 1965; 273:194-8; PMID:14306335; http://dx.doi.org/10.1056/NEJM196507222730404.
19. Santiago Actis A, Sa Fleitas MJ. Relaciones entre viremia y sero-anticuerpos secundarios a la vacu-nación antiamarílica de personas vacundas con "cepa 17D-EP. Rev Sanid Milit Argent 1970; 69:51-63; PMID:5530987.
20. Monath T P, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-18; PMID:11803060; http://dx.doi.org/10.1016/S0264-410X(01)00457-1.
21. Monath T P, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenic-ity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188:1213-30; PMID:14551893; http://dx.doi.org/10.1086/378356.
22. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56:159-67; PMID:9746073; http://dx.doi.org/10.1002/ (SICI)1096-9071(199810)56:2159::AID-JMV103.0.CO;2-B.
23. Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel J T, Visser LG. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS ONE 2008; 3:e1993; PMID:18431480; http://dx.doi.org/10.1371/journal.pone. 0001993.
24. Roukens AH, Soonawala D, Joosten SA, de Visser AW, Jiang X, Dirksen K, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS ONE 2011; 6:e27753; PMID:22163273; http://dx.doi.org/10.1371/journal.pone. 0027753.
25. Domingo C, Yactayo S, Agbenu E, Demanou M, Schulz AR, Daskalow K, et al. Detection of yellow fever 17D genome in urine. J Clin Microbiol 2011; 49:760-2; PMID:21106799; http://dx.doi.org/10.1128/JCM.01775-10.
26. Martínez MJ, Vilella A, Pumarola T, Roldan M, Sequera VG, Vera I, et al. Persistence of yellow fever vaccine RNA in urine. Vaccine 2011; 29:3374-6; PMID:21385635; http://dx.doi.org/10.1016/j.vac-cine.2011.02.075.
27. Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LAB, et al.; Brighton Collaboration Viscerotropic Disease Working Group. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012; 30:5038-58; PMID:22561144; http://dx.doi.org/10.1016/j.vac-cine.2012.04.067.
28. Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, et al. Anamnestic immune response to dengue and decreased severity of yellow Fever. J Glob Infect Dis 2009; 1:111-6; PMID:20300401; http://dx.doi.org/10.4103/0974- 777X.56257.
29. Rabello A, Orsini M, Disch J, Marcial T, Leal M da L, Freire M da S, et al. Low frequency of side effects following an incidental 25 times concentrated dose of yellow fever vaccine. Rev Soc Bras Med Trop 2002; 35:177-80; PMID:12011927; http://dx.doi.org/10.1590/S0037-86822002000200008.
30. Carneiro M, Lara B da S, Schimidt B, Gais L. [Overdose of yellow fever vaccine in the Southern region of Brazil]. Rev Soc Bras Med Trop 2011; 44:252-3; PMID:21552746.
31. Nascimento Silva JR, Camacho LAB, Siqueira MM, Freire M de S, Castro Y P, Maia M de L, et al.; Collaborative Group for the Study of Yellow Fever Vaccines. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011; 29:6327-34; PMID:21640779; http://dx.doi.org/10.1016/j.vac-cine.2011.05.019.
32. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, et al. Randomized, doubleblind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005; 72:189-97; PMID:15741556.
33. Food and Drug Administration. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. U.S. Department of Health and Human Services, 2007.
34. Caufour PS, Motta MC, Yamamura AM, Vazquez S, Ferreira II, Jabor AV, et al. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res 2001; 79:1-14; PMID:11551641; http://dx.doi.org/10.1016/S0168-1702(01)00273-8.
35. National Institute for Biological Standards and Control. WHO reference reagent. The 1st international reference preparation for anti-yellow fever serum monkey NIBSC code: Y F. Available from: http://www.nibsc.ac.uk/documents/ifu/ YF.pdf;2008[cited15.03.2011].
36. Hintze J. 2009. Kaysville, Utah. WWW.NCSS.COM.
37. Abramson JH. WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiol Perspect Innov 2004; 1:6; PMID:15606913; http://dx.doi.org/10.1186/1742-5573-1-6.
38. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.2. www.OpenEpi.com, updated 2007/11/18, accessed 2012/05/02.